NPS kept at market perform by JMP

JMP Securities analyst Charles C. Duncan maintained NPS Pharmaceuticals, Inc. at market perform after the company's restructuring announcement leaves some uncertainty. The restructuring is a much-needed, long-awaited strategic move, according to the analyst, making the company a more attractive acquisition candidate. JMP reduced its 2006 revenue estimate to $27 million from $30 million and lowered its net loss estimate to $2.70 per share from $3.39 per share. Shares of the Salt Lake City-based biopharmaceutical company were up 15 cents, or 3.30%, at $4.69 on volume of 1,099,721 shares versus the three-month running average of 1,134,510 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.